The Current Ratio as of November 2024 (TTM) for UroGen Pharma Ltd. (URGN) is 8.15

According to UroGen Pharma Ltd.’s latest financial reports and current stock price. The company's current Current Ratio is 8.15. This represents a change of 16.02% compared to the average of 7.03 of the last 4 quarters.

UroGen Pharma Ltd. (URGN) Historical Current Ratio (quarterly & annually)

How has URGN Current Ratio performed in the past?

The mean historical Current Ratio of UroGen Pharma Ltd. over the last ten years is 6.75. The current 8.15 Current Ratio has changed 11.97% with respect to the historical average. Over the past ten years (40 quarters), URGN's Current Ratio was at its highest in in the March 2019 quarter at 24.16. The Current Ratio was at its lowest in in the March 2015 quarter at 0.

UroGen Pharma Ltd. (URGN) Current Ratio by Quarter and Year

Discovering the peaks and valleys of UroGen Pharma Ltd. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

UroGen Pharma Ltd. (URGN) Average Current Ratio

How has URGN Current Ratio performed in the past?

The current Current Ratio of UroGen Pharma Ltd. (URGN) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

UroGen Pharma Ltd. (URGN) Current Ratio vs. Peers

How is URGN’s Current Ratio compared to its peers?

UroGen Pharma Ltd.’s Current Ratio is less than Eliem Therapeutics, Inc. (60.41), greater than Inhibrx Biosciences, Inc. (6.20), less than Merrimack Pharmaceuticals, Inc. (10.78), less than Celcuity Inc. (14.95), less than Enliven Therapeutics, Inc. (14.39), less than Ikena Oncology, Inc. (18.22), greater than Xilio Therapeutics, Inc. (2.02), less than Protara Therapeutics, Inc. (16.33), greater than Scholar Rock Holding Corporation (6.04), less than Vaccitech plc (9.21), greater than Generation Bio Co. (7.42), less than Kronos Bio, Inc. (8.49), less than Erasca, Inc. (16.79), greater than C4 Therapeutics, Inc. (6.31), less than Edgewise Therapeutics, Inc. (30.24), greater than Ovid Therapeutics Inc. (5.73), less than Connect Biopharma Holdings Limited (12.04), greater than PepGen Inc. (7.45), less than Tyra Biosciences, Inc. (36.46), less than Compass Therapeutics, Inc. (40.74), less than Vigil Neuroscience, Inc. (8.39), greater than PureTech Health plc (3.68),

Build a custom stock screener for UroGen Pharma Ltd. (URGN) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like UroGen Pharma Ltd. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

UroGen Pharma Ltd. (URGN) and other stocks custom spreadsheet templates

The easiest way to analyze a company like UroGen Pharma Ltd. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.